Endocrinol Metab.  2023 Apr;38(2):282-284. 10.3803/EnM.2022.1643.

Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Positive Vasculitis and Agranulocytosis: A Rare Case with Life-Threatening Multiple Systemic Manifestations

• Kang DH
• Song MK
• Ju SH
• Lee SI
• Kang YE

• KMID: 2541885
• DOI: http://doi.org/10.3803/EnM.2022.1643

Figure

• 

  Fig. 1. The representative images of the patient. (A) Representative images of skin lesion showed that blanching erythematous skin lesions are present on her bilateral lower extremities. (B) Initial chest X-ray at admission was normal. (C) Chest X-ray at the time the patient’s symptoms worsened showed diffuse haziness in both lung fields. (D, E, F) Representative coronal or sagittal images of chest computed tomography revealed diffuse acinar opacities, ground-glass opacity, and septal thickening in both lungs.

Reference

1. Yang J, Yao LP, Dong MJ, Xu Q, Zhang J, Weng WW, et al. Clinical characteristics and outcomes of propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis in patients with graves’ disease: a median 38-month retrospective cohort study from a single institution in China. Thyroid. 2017; 27:1469–74.

2. Chen YX, Yu HJ, Ni LY, Zhang W, Xu YW, Ren H, et al. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol. 2007; 34:2451–6.

3. Tomkins M, Tudor RM, Smith D, Agha A. Propylthiouracilinduced antineutrophil cytoplasmic antibody-associated vasculitis and agranulocytosis in a patient with Graves’ disease. Endocrinol Diabetes Metab Case Rep. 2020; 2020:19–0135.

4. Ortiz-Diaz EO. A 27-year-old woman presenting with refractory hypoxaemic respiratory failure, haemoptysis and thyrotoxicosis: a rare manifestation of propylthiouracil therapy. BMJ Case Rep. 2014; 2014:bcr2014204915.

5. Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid drug-induced agranulocytosis: state of the art on diagnosis and management. Drugs R D. 2017; 17:91–6.